Durvalumab with tarlatamab cut risk of death by 58% in small cell lung cancer trial
In the Phase III DeLLphi-305 trial, Imfinzi plus Amgen's tarlatamab-dlle lowered the death risk by 58% in an interim analysis, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Results from the Phase III DeLLphi-305 trial show that Imfinzi (durvalumab) combined with Amgen's tarlatamab-dlle produced a statistically significant gain in overall survival and progression-free survival versus Imfinzi alone as first-line maintenance. The study enrolled patients with extensive-stage small cell lung cancer who had not progressed after induction with Imfinzi, platinum chemotherapy and etoposide.
In a planned interim analysis, the overall survival hazard ratio was 0.42 (95% CI 0.32–0.54), a 58% reduction in the risk of death. The findings will be presented at the ESMO Congress 2026 in Madrid and were published in the New England Journal of Medicine, according to TradingView.
why it matters
For markets this is a sign of growing competition and partnership value in oncology drugs, relevant to Amgen's pipeline. The result rests on a single trial and interim data, so its commercial weight will depend on regulatory review and later readouts.
tags
instruments
sources
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial — TradingView, 24 October 2026 at 14:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗